International Stem Cell (ISCO) Times Interest Earned (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Times Interest Earned of $2.85 for Q4 2025, up 117.59% year-over-year from $1.31 in Q4 2024, and up 1458.95% quarter-over-quarter from $0.18 in Q3 2025.
International Stem Cell (ISCO) Times Interest Earned (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Times Interest Earned for 16 consecutive years, with $2.85 the latest figure, recorded in Q4 2025.
- In Q4 2025, Times Interest Earned rose 117.59% year-over-year to $2.85; the TTM figure through Dec 2025 stood at $1.98 (up 126.18% YoY), while the FY2025 annual figure was -$0.03, down 288.13% from the prior year.
- Times Interest Earned grew to $2.85 in Q4 2025 per ISCO's latest filing, from $0.18 in the prior quarter.
- Across five years, Times Interest Earned topped out at $4.28 in Q4 2023 and bottomed at -$10.42 in Q4 2021.
- Historically, Times Interest Earned has averaged -$1.3 across 5 years, with a median of -$0.46 in 2022.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 795.08% — and 2024, when it tumbled 3825.58%.
- International Stem Cell's Times Interest Earned stood at -$10.42 in 2021, then surged by 94.09% to -$0.62 in 2022, then soared by 795.08% to $4.28 in 2023, then plunged by 69.47% to $1.31 in 2024, then soared by 117.59% to $2.85 in 2025.
- Business Quant data shows ISCO's Times Interest Earned at $2.85 in Q4 2025, $0.18 in Q3 2025, and $0.27 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.42 |
| 10 | International Stem Cell | 3.20 Mn | 2.11 Mn | 1.46 Mn | -1.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.09 |
| Dec 31, 2025 | 2.85 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.27 |
| Mar 31, 2025 | -0.30 |
| Dec 31, 2024 | 1.31 |
| Sep 30, 2024 | -2.57 |
| Jun 30, 2024 | 0.23 |
| Mar 31, 2024 | -2.07 |
| Dec 31, 2023 | 4.28 |
| Sep 30, 2023 | -2.85 |
| Jun 30, 2023 | -4.11 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | -0.62 |
| Sep 30, 2022 | -8.57 |
| Jun 30, 2022 | 0.94 |
| Mar 31, 2022 | 0.74 |
| Dec 31, 2021 | -10.42 |
| Sep 30, 2021 | -1.98 |
| Jun 30, 2021 | -0.82 |